Pembrolizumab

What is Pembrolizumab?

Pembrolizumab, pronounced pem-broh-LIZ-yoo-mab, is a monoclonal antibody used in cancer immunotherapy. It is marketed under the brand name Keytruda and is available in injectable form. Pembrolizumab belongs to a class of drugs known as PD-1 inhibitors, which help the immune system to detect and fight cancer cells more effectively. It is typically administered intravenously in a clinical setting.

What conditions or symptoms is Pembrolizumab used to treat?

Pembrolizumab is used to treat various types of cancer, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and more. It is often prescribed when other treatments have failed or when the cancer is advanced. If you are experiencing symptoms such as persistent cough, unexplained weight loss, or unusual lumps, you might want to discuss these with your healthcare provider. You are having these symptoms, please check them here:Check your persistent cough, unexplained weight loss, or unusual lumps symptoms here.

How does Pembrolizumab work in the body?

Pembrolizumab works by blocking a protein called PD-1 on the surface of immune cells. This protein normally acts as a brake on the immune system, preventing it from attacking the body's own tissues. By inhibiting PD-1, Pembrolizumab releases this brake, allowing the immune system to recognize and destroy cancer cells more effectively. This mechanism of action is a form of immunotherapy, which leverages the body's natural defenses to fight cancer.

In what forms is Pembrolizumab available?

Pembrolizumab is available as a solution for intravenous infusion. It is supplied in single-use vials containing a concentrated solution that must be diluted before administration. The dosage and frequency of administration depend on the type of cancer being treated and the patient's overall health. Healthcare providers administer Pembrolizumab in a clinical setting to ensure proper handling and monitoring during the infusion process.

What are the most common side effects of Pembrolizumab?

• Fatigue
• Rash
• Nausea
• Diarrhea
• Decreased appetite

These side effects are generally mild to moderate in severity and can often be managed with supportive care. Patients should report any persistent or bothersome side effects to their healthcare provider for further evaluation and management.

What are the serious or severe side effects of Pembrolizumab?

• Severe immune-mediated reactions
• Hepatitis
• Pneumonitis
• Nephritis
• Endocrinopathies

These severe side effects require immediate medical attention and may necessitate discontinuation of the drug. Patients should be closely monitored for signs of these adverse reactions, and healthcare providers should be informed promptly if they occur.

How should Pembrolizumab be stored safely?

Pembrolizumab should be stored in a refrigerator at temperatures between 2°C to 8°C (36°F to 46°F) and protected from light. It should not be frozen or shaken. Once diluted for infusion, the solution should be used promptly or stored under specific conditions as directed by healthcare professionals. Proper storage ensures the drug's efficacy and safety for patient use.

What are the overall side effects of Pembrolizumab?

Pembrolizumab can cause a range of side effects, from mild to severe. Common side effects include fatigue, rash, and nausea, while serious side effects may involve immune-mediated reactions affecting vital organs. Patients should be aware of these potential side effects and communicate any unusual symptoms to their healthcare provider. Regular monitoring and follow-up appointments are essential to manage these effects effectively.

What warnings or precautions should be considered when taking Pembrolizumab?

Patients receiving Pembrolizumab should be aware of the potential for immune-mediated side effects, which can affect various organs. Regular monitoring and prompt reporting of symptoms are crucial. Additionally, Pembrolizumab may not be suitable for individuals with certain pre-existing conditions, and it is important to discuss all health concerns with a healthcare provider before starting treatment. Pregnant or breastfeeding women should also consult their doctor due to potential risks to the fetus or infant.

Who should avoid using Pembrolizumab?

Pembrolizumab may not be suitable for individuals with certain autoimmune disorders, as it can exacerbate these conditions. Patients with a history of severe allergic reactions to monoclonal antibodies should also avoid this medication. Additionally, those with active infections or certain pre-existing health conditions should discuss the risks and benefits with their healthcare provider before initiating treatment with Pembrolizumab.

What important information should I know before using Pembrolizumab?

Before starting Pembrolizumab, patients should inform their healthcare provider about all medical conditions, including any history of autoimmune diseases, liver or kidney problems, and any previous reactions to similar medications. It is also important to disclose all current medications, including over-the-counter drugs and supplements, to avoid potential interactions. Understanding the potential side effects and the importance of regular monitoring can help patients manage their treatment effectively.

What should I discuss with my healthcare provider before starting Pembrolizumab?

Patients should discuss their complete medical history, including any previous cancer treatments and their outcomes, with their healthcare provider. It is also important to talk about any current medications, supplements, or herbal products being taken, as these could interact with Pembrolizumab. Additionally, patients should inquire about the potential side effects and the monitoring process during treatment to ensure they are fully informed and prepared for the therapy.

Does Pembrolizumab interact with any foods or beverages?

While Pembrolizumab does not have specific food or beverage interactions, patients should maintain a balanced diet and stay hydrated during treatment. It is advisable to consult with a healthcare provider or nutritionist for personalized dietary recommendations, especially if experiencing side effects like nausea or loss of appetite. Maintaining overall health and nutrition can support the body's ability to cope with cancer treatment.

Does Pembrolizumab have interactions with other medications?

Pembrolizumab may interact with other medications, particularly those that affect the immune system. Patients should provide a complete list of all medications, including prescription drugs, over-the-counter medications, and supplements, to their healthcare provider. This information helps in assessing potential interactions and adjusting treatment plans accordingly to ensure the safety and efficacy of Pembrolizumab therapy.

What should I do if I accidentally take too much Pembrolizumab?

In the event of an overdose of Pembrolizumab, it is crucial to seek immediate medical attention. Overdosing can increase the risk of severe side effects and complications. Healthcare providers will monitor the patient closely and provide supportive care as needed. It is important to adhere to the prescribed dosage and schedule to avoid such occurrences.

What should I do if I miss a dose of Pembrolizumab?

If a dose of Pembrolizumab is missed, patients should contact their healthcare provider as soon as possible to reschedule the infusion. It is important not to double up on doses to make up for a missed one. Healthcare providers will provide guidance on how to proceed and adjust the treatment schedule if necessary to maintain the effectiveness of the therapy.

What signs or symptoms should I watch for while taking Pembrolizumab?

Patients should be vigilant for signs of immune-mediated side effects, such as new or worsening cough, chest pain, shortness of breath, or changes in bowel habits. Other symptoms to watch for include unusual fatigue, skin rash, or changes in vision. Promptly reporting these symptoms to a healthcare provider can help in early detection and management of potential complications, ensuring the safety and effectiveness of the treatment.

When was Pembrolizumab first developed and approved by the FDA?

Pembrolizumab was first developed by Merck & Co., Inc. and received its initial FDA approval in September 2014 for the treatment of advanced melanoma. Since then, its indications have expanded to include a variety of cancers, reflecting its effectiveness and versatility as an immunotherapy agent. The development and approval of Pembrolizumab marked a significant advancement in cancer treatment, offering new hope to patients with challenging diagnoses.